147 related articles for article (PubMed ID: 23320888)
1. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.
Hlubocky FJ; Webster K; Beaumont J; Cashy J; Paul D; Abernethy A; Syrjala KL; Von Roenn J; Cella D
Leuk Lymphoma; 2013 Sep; 54(9):1942-6. PubMed ID: 23320888
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22).
Pearman TP; Beaumont JL; Paul D; Abernethy AP; Jacobsen PB; Syrjala KL; Von Roenn J; Cella D
J Pain Symptom Manage; 2013 Jul; 46(1):113-20. PubMed ID: 23017622
[TBL] [Abstract][Full Text] [Related]
3. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
Rothrock NE; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Cella D
Value Health; 2013; 16(5):789-96. PubMed ID: 23947972
[TBL] [Abstract][Full Text] [Related]
4. Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).
Garcia SF; Rosenbloom SK; Beaumont JL; Merkel D; Von Roenn JH; Rao D; Cella D
Value Health; 2012 Jan; 15(1):183-90. PubMed ID: 22264987
[TBL] [Abstract][Full Text] [Related]
5. EORTC QLQ-C30 and FACT-Lym for the assessment of health-related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy.
Georgakopoulos A; Kontodimopoulos N; Chatziioannou S; Niakas D
Eur J Oncol Nurs; 2013 Dec; 17(6):849-55. PubMed ID: 23850411
[TBL] [Abstract][Full Text] [Related]
6. A new index of priority symptoms in advanced ovarian cancer.
Jensen SE; Rosenbloom SK; Beaumont JL; Abernethy A; Jacobsen PB; Syrjala K; Cella D
Gynecol Oncol; 2011 Feb; 120(2):214-9. PubMed ID: 21075440
[TBL] [Abstract][Full Text] [Related]
7. Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index.
Jensen SE; Beaumont JL; Jacobsen PB; Abernethy A; Syrjala KL; Cella D
J Support Oncol; 2013 Jun; 11(2):86-93. PubMed ID: 23089235
[TBL] [Abstract][Full Text] [Related]
8. A brief symptom index for advanced lung cancer.
Yount S; Beaumont J; Rosenbloom S; Cella D; Patel J; Hensing T; Jacobsen PB; Syrjala K; Abernethy AP
Clin Lung Cancer; 2012 Jan; 13(1):14-23. PubMed ID: 21729652
[TBL] [Abstract][Full Text] [Related]
9. Translation and validation of the Traditional Chinese version of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (Version 2).
Chan DNS; Choi KC; Ng MSN; Xing W; Law BMH; Ho PS; Au C; Chan M; Tong M; Ling WM; Chan M; Mak SSS; Chan RJ; So WKW
Health Qual Life Outcomes; 2021 Jan; 19(1):17. PubMed ID: 33419447
[TBL] [Abstract][Full Text] [Related]
10. Development of a symptom index for patients with primary brain tumors.
Lai JS; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Raizer JJ; Cella D
Value Health; 2014; 17(1):62-9. PubMed ID: 24438718
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).
Butt Z; Parikh ND; Beaumont JL; Rosenbloom SK; Syrjala KL; Abernethy AP; Benson AB; Cella D
Cancer; 2012 Dec; 118(23):5997-6004. PubMed ID: 22605658
[TBL] [Abstract][Full Text] [Related]
12. Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Trigg A; Kelly M; Iadeluca L; Chang J; Moreno-Koehler A; Yaworsky A; Krohe M; Rider A; Cappelleri JC; Cella D; Cocks K
Future Oncol; 2021 Oct; 17(30):3951-3964. PubMed ID: 34287020
[TBL] [Abstract][Full Text] [Related]
13. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).
Yount S; Cella D; Banik D; Ashraf T; Shevrin D
Health Qual Life Outcomes; 2003 Nov; 1():69. PubMed ID: 14633279
[TBL] [Abstract][Full Text] [Related]
14. Psychometric Properties of the Arabic Version of the Functional Assessment of Chronic Illnesses Therapy-Fatigue in Arabic Cancer Patients.
Al Maqbali M; Hughes C; Gracey J; Rankin J; Hacker E; Dunwoody L
J Pain Symptom Manage; 2020 Jan; 59(1):130-138.e2. PubMed ID: 31647976
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
16. Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Palliative care (FACIT-Pal) scale.
Lyons KD; Bakitas M; Hegel MT; Hanscom B; Hull J; Ahles TA
J Pain Symptom Manage; 2009 Jan; 37(1):23-32. PubMed ID: 18504093
[TBL] [Abstract][Full Text] [Related]
17. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.
Portenoy RK; Thaler HT; Kornblith AB; Lepore JM; Friedlander-Klar H; Kiyasu E; Sobel K; Coyle N; Kemeny N; Norton L
Eur J Cancer; 1994; 30A(9):1326-36. PubMed ID: 7999421
[TBL] [Abstract][Full Text] [Related]
18. Translation and validation of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) version 4 quality of life instrument into Arabic language.
Soudy H; Maghfoor I; Elhassan TAM; Abdullah E; Rauf SM; Al Zahrani A; Akhtar S
Health Qual Life Outcomes; 2018 Mar; 16(1):47. PubMed ID: 29530033
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore.
Chan A; Lew C; Wang XJ; Ng T; Chae JW; Yeo HL; Shwe M; Gan YX
Health Qual Life Outcomes; 2018 Jan; 16(1):20. PubMed ID: 29351803
[TBL] [Abstract][Full Text] [Related]
20. Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.
Boileau NR; Stout JC; Paulsen JS; Cella D; McCormack MK; Nance MA; Frank S; Lai JS; Carlozzi NE
J Huntingtons Dis; 2017; 6(3):201-215. PubMed ID: 28968239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
